Current Treatment Landscape for AL Amyloidosis

EP: 1.Exploring the Landscape Surrounding Light Chain Amyloidosis

EP: 2.Expert Perspectives on Differentiating Signs and Symptoms in AL Amyloidosis Diagnosis

EP: 3.Exploring Diagnostic Approaches for Patients with Light Chain Amyloidosis

Now Viewing

EP: 4.Current Treatment Landscape for AL Amyloidosis

EP: 5.Unmet Needs and Treatment Considerations in Managing AL Amyloidosis

EP: 6.Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

EP: 7.Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs

EP: 8.Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

EP: 9.The Role of Cardiac Staging in Patients with AL Amyloidosis

EP: 10.Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

EP: 11.AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

EP: 12.Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

EP: 13.The Potential Role of CAR T Therapy in AL Amyloidosis

EP: 14.NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

EP: 15.Looking Ahead: Future Perspectives on AL Amyloidosis

This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.

Panelists discuss the treatment landscape for light chain (AL) amyloidosis, focusing on targeting plasma cells to reduce toxic light chains. They note challenges in adapting multiple myeloma therapies for amyloidosis due to tolerability issues with certain agents. The primary FDA-approved induction regimen is cyclophosphamide-bortezomib-dexamethasone (CyBorD), which demonstrates effectiveness in reducing misfolded light chains, especially with the addition of the monoclonal antibody daratumumab.

Although the regimen significantly improves organ function, it does not impact early survival rates, particularly for patients at high risk of complications. The discussion highlights the ongoing complexities in treating AL amyloidosis, such as balancing effectiveness and survival outcomes.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.